Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M45,923Revenue $M2,820Net Margin (%)12.3Z-Score23.4
Enterprise Value $M45,933EPS $3.1Operating Margin %29.7F-Score5
P/E(ttm))146Cash Flow Per Share $-2.0Pre-tax Margin (%)27.5Higher ROA y-yN
Price/Book17.710-y EBITDA Growth Rate %0Quick Ratio3.1Cash flow > EarningsY
Price/Sales18.05-y EBITDA Growth Rate %0Current Ratio3.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %2.8ROA % (ttm)10.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)15.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M103ROI % (ttm)53.3Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 447.5212%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 447.5212%Sold Out0
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 447.5225%Add 60.05%1,410
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 447.5225%New holding583
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 447.5234%Add 60.34%2,795,500
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 447.5234%New holding881
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 447.5234%New holding2,295
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 447.5232%Add 23.47%1,743,468
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 447.5231%New holding6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 447.5236%Sold Out0
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 447.5241%New holding3,285
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 447.5262%Add 170.41%1,412,100
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 447.5270%Reduce -24.56%522,200
REGNDodge & Cox 2012-03-31 Sold Out $57.83 - $119.96
($92.23)
$ 447.5279%Sold Out0
REGNCarl Icahn 2011-09-30 Sold Out -1.76%$44.96 - $72.19
($58.66)
$ 447.5287%Sold Out0
REGNDodge & Cox 2011-09-30 Reduce-0.03%$44.96 - $72.19
($58.66)
$ 447.5287%Reduce -97.62%9,400
REGNVanguard Health Care Fund 2011-09-30 Add0.03%$44.96 - $72.19
($58.22)
$ 447.5287%Add 15.37%692,200
REGNDodge & Cox 2011-03-31 Buy 0.02%$32.61 - $44.68
($36.41)
$ 447.5292%New holding375,685
REGNVanguard Health Care Fund 2011-03-31 Reduce$32.61 - $44.94
($36.59)
$ 447.5292%Reduce -3.21%600,000
REGNSeth Klarman 2011-03-31 Sold Out $32.61 - $44.68
($36.41)
$ 447.5292%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAKER CHARLES ADirector 2015-03-25Sell5,000$454.960.44view
Aberman Michael SSVP Strategy Investor Relation 2015-03-24Sell4,843$478.99-4.6view
Aberman Michael SSVP Strategy Investor Relation 2015-03-18Sell3,442$465-1.72view
Terifay Robert JSVP Commercial 2015-03-17Sell10,993$451.011.32view
LAROSA JOSEPH JSVP General Counsel and Secret 2015-03-16Sell18,311$4501.55view
McCorkle Douglas SVP Controller and Asst Treasur 2015-02-27Sell3,000$416.249.79view
Tessier-Lavigne MarcDirector 2015-02-26Sell3,000$421.958.3view
Terifay Robert JSVP Commercial 2015-02-24Sell11,173$423.677.86view
Aberman Michael SSVP Strategy Investor Relation 2015-02-24Sell3,374$418.489.2view
Van Plew Daniel PSVP & General Mgr Industrial O 2015-02-23Sell9,431$427.826.82view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
    1 Feb 23 2015 
    1 Feb 23 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 

    More From Our Partners
    Stock Market News for April 09, 2015 - Market News Apr 9 2015 - ZACKS

    More From Other Websites
    Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and... Apr 10 2015
    Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and... Apr 10 2015
    Cramer: How to play the Apple downgrade Apr 08 2015
    Stock Market News for April 08, 2015 - Market News Apr 08 2015
    Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM)... Apr 07 2015
    FedEx gains on TNT deal; GM slides as Canada unwinds stake Apr 07 2015
    Don't Miss Your Chance To Buy This High-Ranking Biotech On Sale Apr 03 2015
    Biotech run near an end? Apr 02 2015
    Economic Indicators Move Equities and Bonds Apr 01 2015
    Esperion Up As UBS Touts Cholesterol Drug Apr 01 2015
    Stocks Tumble In Heavy Trade; Twitter And Sears Holdings Gain Apr 01 2015
    Cramer: The best places for you to put new money Mar 30 2015
    Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog Mar 30 2015
    Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List Mar 30 2015
    Cramer Remix: A bottom in biotech? Hardly Mar 27 2015
    Cramer: 4 horsemen of biotech & semis are back Mar 27 2015
    Stocks Finish Lower for the Week as Fed Talk Spooks Investors Mar 27 2015
    11 promising drugs poised to be the next billion-dollar blockbusters Mar 27 2015
    Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog Mar 26 2015
    Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks Mar 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK